Equities

Biovica International AB

Biovica International AB

Actions
  • Price (SEK)1.87
  • Today's Change0.068 / 3.78%
  • Shares traded42.23k
  • 1 Year change-29.04%
  • Beta1.4509
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

  • Revenue in SEK (TTM)7.25m
  • Net income in SEK-115.45m
  • Incorporated2008
  • Employees27.00
  • Location
    Biovica International ABDag Hammarskjolds vag 54BUppsala Science ParkUPPSALA 752 37SwedenSWE
  • Phone+46 184444830
  • Fax+46 18572428
  • Websitehttps://biovica.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Coegin Pharma AB0.00-26.00m99.47m1.00--3.79-----2.25-2.250.001.060.00-------111.12-122.02-119.99-154.70-------28,466.75---55.530.00------20.60------
AroCell AB (publ)51.58m-50.57m101.82m----0.782--1.97-0.2195-0.21950.22390.56530.30836.535.54---30.22-29.25-32.55-31.3712.55-9.85-98.04-231.194.52--0.00--16.37122.92-0.5494------
Prolight Diagnostics AB (publ)0.00-140.00m103.91m16.00--0.6049-----0.3853-0.38530.000.24470.00----0.00-66.82---89.89--------------0.00-----------13.84--
Sprint Bioscience AB60.25m-19.11m106.27m36.00--7.88--1.76-0.2737-0.27370.8630.19311.10--7.282,151,857.00-34.81-71.22-82.55-113.7158.5462.75-31.72-110.22----0.00--60,725.3022.9999.27---26.02--
Lumito AB (publ)17.00k-31.86m124.32m13.00--1.29--7,313.17-0.1472-0.14720.000080.41330.0001--2.431,133.33-26.73-20.77-30.85-22.3842,235.47---187,433.80--1.10-14.600.1715------4.56------
NextCell Pharma AB10.66m-41.96m128.64m24.00--1.90--12.06-0.8409-0.84090.20950.92490.125455.565.31444,362.90-49.33-35.01-55.89-37.45-247.97-304.79-393.45-468.526.09--0.00--5.4542.54-5.40---27.06--
Kancera AB0.00-53.07m130.64m5.00--1.57-----0.5955-0.59550.000.68490.00----0.00-56.73-54.82-66.40-66.21--96.28---7,249.06----0.00-------23.64------
Biovica International AB7.25m-115.45m151.33m27.00--1.69--20.87-1.73-1.730.10551.060.058417.304.76226,593.80-92.98-51.94-110.37-58.18-394.72-576.01-1,592.15-2,217.413.47--0.0721--115.4919.39-12.97---54.31--
Acousort AB3.44m-19.30m170.25m----11.13--49.51-1.33-1.330.23791.020.14614.081.96---81.99-48.62-137.70-69.77-159.41-68.05-561.21-299.581.91--0.00--11.5138.81-24.01------
Biosergen AB0.00-23.42m170.97m2.00--7.49-----0.2273-0.22730.000.08220.00----0.00-179.89---244.13--------------0.00------32.25------
Exact Therapeutics AS0.00-54.78m182.68m12.00--10.49-----1.66-1.660.000.54350.00-------130.29-40.21-170.98-45.67------------0.0502-------20.52------
Intervacc AB9.29m-77.34m192.37m15.00--1.07--20.72-1.02-1.020.12262.380.03865.091.59619,066.70-32.15-17.62-35.27-18.77-432.03-243.59-832.82-626.902.26--0.0006---17.23-25.79-60.31---38.72--
ViroGates A/S6.52m-20.56m198.30m10.00--15.00--30.40-5.64-5.640.83381.100.29350.46673.62419,900.00-92.50-46.58-105.88-52.0957.2577.91-315.15-238.016.13-19.840.4278---45.0110.98-25.40------
Xintela AB381.00k-40.83m200.20m--------525.47-0.0817-0.08170.0008-0.03190.0306--0.0493---327.65-181.06---391.61100.00---10,717.06-235,894.00---203.91-------45.5418.32---61.47--
SenzaGen AB-100.00bn-100.00bn206.53m33.00--2.31----------3.03-----------25.84---29.85--68.62---132.293.18--0.0225--19.3990.3211.30---21.10--
Lifecare ASA15.06m-59.78m208.26m32.00--0.1789--13.83-16.49-16.491.5173.510.1698--1.56471,007.80-67.36-40.00-86.96-45.26-----396.68-175.53----0.1102---40.8830.29-101.74------
Data as of Nov 22 2024. Currency figures normalised to Biovica International AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.33%Per cent of shares held by top holders
HolderShares% Held
Deka Investment GmbHas of 31 Mar 2024264.16k0.31%
FCG Fonder ABas of 31 Oct 202415.69k0.02%
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.